(:AVEO)

Mar 28, 2024 03:22 pm ET
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
In a release issued under the same headline on March 25 by AVEO Pharmaceuticals, the text in the second paragraph has been corrected to better reflect Dr. Braendle's clinical research experience. The corrected release follows: AVEO Oncology...
Mar 25, 2024 08:10 am ET
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to...
Feb 06, 2024 08:10 am ET
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncol
AVEO Oncology, an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA® (tivozanib) in...
Jan 16, 2024 07:30 am ET
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and
AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination...
Jan 19, 2023 04:35 pm ET
LG Chem Completes Acquisition of AVEO Oncology
LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that...
Jan 05, 2023 07:35 pm ET
AVEO Oncology Stockholders Approve Acquisition by LG Chem
AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the...
Jan 03, 2023 08:16 am ET
AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders
AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO’s Special...
Nov 10, 2022 09:35 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OFIX, AAWW, AVEO, MYOV
NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 09, 2022 07:11 pm ET
Lifshitz Law PLLC Announces Investigations of RBA, AKUS, AVEO, and CLR
Ritchie Bros. Auctioneers Incorporated (NYSE: RBA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of IAA, Inc. to RBA for $10.00 per share in cash and 0.5804 shares of RBA common...
Nov 07, 2022 04:05 pm ET
AVEO Oncology Reports Third Quarter 2022 Financial Results
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today reported financial results for the third quarter ended...
Nov 03, 2022 03:56 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BNFT, ATCO, ABMD, AVEO
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Benefitfocus, Inc. (NASDAQ: BNFT)’s...
Oct 31, 2022 06:25 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVEO, PEBO, LMST, MYOV
NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 31, 2022 01:07 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Altra Industrial Motion Corp. (Nasdaq - AIMC), UserTesting, Inc. (NYSE - USER), AVEO Pharmaceuticals, Inc. (Na
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is...
Oct 28, 2022 08:29 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LFG, CLR, AVEO, AKUS
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Archaea Energy Inc. (NYSE: LFG)’s sale...
Oct 25, 2022 10:35 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LFG, CLR, AVEO, AKUS
NEW YORK, Oct. 25, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 24, 2022 09:40 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of AVEO Pharmaceuticals, Inc. - AVEO
NEW YORK, Oct. 24, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating AVEO Pharmaceuticals, Inc. (AVEO), relating to its proposed acquisition by LG Chem, Ltd. Under the terms of the agreement, AVEO shareholders are expected to receive $15.00 in cash per share they own. Click here for more information: https
Oct 23, 2022 09:43 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CLR, AVEO, AKUS, AYLA
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Continental Resources, Inc. (NYSE:...
Oct 21, 2022 03:31 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates AVEO Pharmaceuticals, Inc.
NEW YORK, Oct. 21, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ: AVEO), in connection with the proposed acquisition of the Company by LG Chem, Ltd. Under the terms of the merger agreement, the Company's shareholders will receive $15.00 in cash for each share of AVEO common stock owned. The transaction is valued at approximately $566 million. 
Oct 18, 2022 08:45 pm ET
AVEO ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AVEO Oncology - AVEO
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AVEO Oncology (NasdaqCM: AVEO) to LG Chem, Ltd. Under the terms of the proposed transaction, shareholders of AVEO will receive only $15.00 in cash for each share of AVEO that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 18, 2022 07:59 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LFG, AVEO, AKUS, CLR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Archaea Energy Inc. (NYSE: LFG)’s sale...
Oct 18, 2022 11:30 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKUS, AVEO, LFG, CLR
NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 18, 2022 10:30 am ET
Shareholder Alert: Ademi LLP investigates whether AVEO Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with LG Chem
MILWAUKEE, Oct. 18, 2022 /PRNewswire/ -- Ademi LLP is investigating AVEO (NASDAQ: AVEO) for possible breaches of fiduciary duty and other violations of law in its transaction with LG Chem. 
Oct 18, 2022 08:30 am ET
Thinking about buying stock in RA Medical, Aveo Pharmaceuticals, FuboTV, Canoo, or 89bio?
NEW YORK, Oct. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RMED, AVEO, FUBO, GOEV, and ETNB.
Oct 18, 2022 08:15 am ET
AVEO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of AVEO Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) to LG Chem, Ltd. for $15.00 per share is fair to AVEO shareholders.
Oct 18, 2022 04:30 am ET
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) and AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced...
Oct 12, 2022 04:05 pm ET
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that, as disclosed on uspto.gov, the United States...
Sep 21, 2022 08:30 am ET
AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that Michael Bailey, president and chief executive...
Aug 31, 2022 08:30 am ET
AVEO Oncology Announces Participation at Investor Conferences in September
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of its senior management team are...
Aug 04, 2022 04:05 pm ET
AVEO Oncology Reports Second Quarter 2022 Financial Results
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today reported financial results for the second quarter ended June...
Jul 28, 2022 04:05 pm ET
AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022. AVEO’s management team will host a conference call...
Jun 22, 2022 08:00 am ET
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with R
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement in North America with Eli Lilly and Company (Lilly) to...
Jun 21, 2022 08:00 am ET
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC...
Jun 06, 2022 08:00 am ET
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology focused biopharmaceutical company, presented three posters during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting highlighting data for tivozanib, the Company’s oral,...
May 18, 2022 08:30 am ET
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on...
May 05, 2022 07:00 am ET
AVEO Oncology Reports First Quarter 2022 Financial Results
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2022. “We recently celebrated the one-year anniversary of our U.S. commercial...
Apr 28, 2022 08:30 am ET
AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. AVEO’s management team will host a conference call and...
Mar 14, 2022 07:00 am ET
AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided financial guidance for 2022. “We have seen...
Mar 07, 2022 08:30 am ET
AVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial results on Monday, March 14, 2022. AVEO’s management team will host a conference call and...
Feb 22, 2022 07:00 am ET
Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
NEW YORK and BOSTON, Feb. 22, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies and AVEO Oncology (NASDAQ: AVEO) ("AVEO"), a commercial stage, oncology-focused biopharmaceutical company, today announced that they have entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, also known as HER3. Actinium will utilize its AWE technology platform and extensive radiotherapy know-how to conjugate one of AVEO's ErbB3 target
Feb 14, 2022 05:01 pm ET
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that new long-term progression free survival (PFS) data from the Phase 3 TIVO-3 study, which compares FOTIVDA® (tivozanib) to Nexavar®...
Feb 03, 2022 08:00 am ET
AVEO Oncology Announces Participation at the 11th Annual SVB Leerink Global Healthcare Conference
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference...
Jan 20, 2022 08:00 am ET
AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that new efficacy and safety data from the first line (cohort A) of the phase 1b/2 DEDUCTIVE study of FOTIVDA® (tivozanib) in combination...
Jan 05, 2022 08:00 am ET
NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment
NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate NKT2152, NiKang’s small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with FOTIVDA® (tivozanib), AVEO’s oral, next-generation vascular endothelial growth factor rece
Jan 04, 2022 08:05 am ET
AVEO Oncology Highlights Recent Progress and 2022 Outlook
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022. “I am proud of the entire AVEO team this year, as we accomplished several key...
Jan 04, 2022 08:00 am ET
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany to evaluate ficlatuzumab...
Dec 22, 2021 08:00 am ET
AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 Conference
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking...
Dec 01, 2021 07:00 am ET
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operational functions key to maximizing the Company’s organizational efficiency and advancing its pipeline of products.
Nov 10, 2021 07:00 am ET
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in two upcoming virtual investor conferences:
Nov 08, 2021 04:05 pm ET
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.
Nov 01, 2021 07:00 am ET
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, November 8, 2021, to discuss the financial results and provide a business update.
Sep 20, 2021 09:31 am ET
Thinking about buying stock in Edesa Biotech, AVEO Pharmaceuticals, Lucid Group, FuelCell Energy, or Nikola Corp?
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EDSA, AVEO, LCID, FCEL, and NKLA.
Sep 20, 2021 07:00 am ET
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma (R/R HNSCC). Ficlatuzumab is AVEO’s investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor.
Aug 30, 2021 07:00 am ET
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
AVEO Oncology (Nasdaq: AVEO) today announced that members of its senior management team will participate in two upcoming virtual investor conferences:
Aug 05, 2021 04:05 pm ET
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021, and provided a business update.
Jul 29, 2021 07:00 am ET
AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 5, 2021, to discuss the financial results and provide a business update.
Jul 08, 2021 04:05 pm ET
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) webinar focusing on FOTIVDA® (tivozanib), AVEO’s oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies, on Friday, July 16, 2021 at 12:00 p.m. Eastern Time.
Jun 07, 2021 07:00 am ET
AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader webinar focusing on ficlatuzumab, the Company’s investigational potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF), being studied in head and neck squamous cell carcinoma (HNSCC) on Wednesday, June 16, 2021 at 2:00 p.m. Eastern Time.
May 25, 2021 07:00 am ET
AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. Eastern Time.
May 19, 2021 05:02 pm ET
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the presentation of additional data from the Phase 3 TIVO-3 study comparing FOTIVDA® (tivozanib) to sorafenib in relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. The data, which includes updated durability of response (DOR) and overall survival (OS) results, as well as an analysis of treatment-emergent adverse events (TEAEs) across study arms, will be featured in two poster presentations at the 2021 American So
May 19, 2021 05:01 pm ET
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced results from a randomized confirmatory Phase 2 study of ficlatuzumab as a single agent or in combination with cetuximab (ERBITUX®), an EGFR-targeted antibody, in patients who relapsed or were refractory to prior immunotherapy, chemotherapy, and cetuximab (pan-refractory) with metastatic head and neck squamous cell carcinoma (HNSCC). Ficlatuzumab is AVEO’s potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF). The res
May 10, 2021 04:05 pm ET
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.
May 03, 2021 07:00 am ET
AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021 financial results on Monday, May 10, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 10, 2021, to discuss the financial results and provide a business update.
Apr 16, 2021 07:00 am ET
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company’s Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and director of the Program in Oncology at the University of Maryland School of Medicine. He also serves as director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Mar 29, 2021 07:00 am ET
AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines
AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma (ccRCC). On March 10, 2021, the U.S. Food and Drug Administration (FDA) approved FOTIVDA for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior system
Mar 26, 2021 04:01 pm ET
AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the full exercise by the underwriters of their option to purchase an additional 900,000 shares, at a price to the public of $8.00 per share. The aggregate gross proceeds to AVEO from the offering were $55.2 million, before deducting underwriting discounts and commissions and offering expenses payable by AVEO.
Mar 23, 2021 10:32 pm ET
AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock
AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share. The gross proceeds to AVEO from the offering are expected to be $48.0 million before deducting underwriting discounts and commissions and offering expenses. All of the shares in the offering are being sold by AVEO. AVEO has also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock on the same terms and conditions. Closing of the offering is exp
Mar 22, 2021 04:01 pm ET
AVEO Announces Proposed Public Offering of Common Stock
AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. All of the shares in the offering are to be sold by AVEO. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Mar 22, 2021 07:00 am ET
AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance
AVEO Oncology (Nasdaq: AVEO) today announced that FOTIVDA® (tivozanib) is now commercially available in the United States (U.S.) ahead of the previous March 31, 2021 guidance. On March 10, 2021, the U.S. Food and Drug Administration (FDA) approved FOTIVDA for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
Mar 16, 2021 04:05 pm ET
AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update
AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update.
Mar 15, 2021 07:00 am ET
AVEO Oncology to Regain Ex-North American Rights to AV-203
AVEO Oncology (Nasdaq: AVEO) today announced that it will regain its rights to AV-203 outside of North America, its clinical-stage potent humanized IgG1 monoclonal antibody that targets ErbB3 (also known as HER3), following the voluntary termination of its collaboration and license agreement by CANbridge Life Sciences. AVEO will regain rights to AV-203 in all territories outside of North America, and CANbridge has initiated the process to transfer all preclinical data and materials to AVEO. The transfer of rights and termination of the collaboration and license agreement will become effective
Mar 12, 2021 07:00 am ET
AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Car
AVEO Oncology (Nasdaq: AVEO) today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate FOTIVDA® (tivozanib) in combination with OPDIVO® (nivolumab), Bristol Myers Squibb’s anti-PD-1 therapy, in the pivotal Phase 3 TiNivo-2 trial in patients with advanced relapsed or refractory renal cell carcinoma (RCC) following prior immunotherapy exposure. FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) approved for the treatment of adult patients with
Mar 11, 2021 04:05 pm ET
AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility
AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates. This second tranche was made available in connection with the recent U.S. Food and Drug Administration (FDA) approval of FOTIVDA® (tivozanib).
Mar 10, 2021 05:52 pm ET
AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer
AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO’s commercial strategy and operations, including the commercialization of FOTIVDA® (tivozanib). FOTIVDA is AVEO’s differentiated oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Mar 10, 2021 03:25 pm ET
AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA® (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies. FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
Mar 02, 2021 07:00 am ET
AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021.
Feb 18, 2021 07:00 am ET
AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m. Eastern Time.
Feb 11, 2021 07:00 am ET
AVEO Oncology Announces Presentation of Key Subgroup and Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO) today announced the presentation of two analyses of the Company’s pivotal TIVO-3 study, its Phase 3 trial comparing tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, to sorafenib in third- and fourth-line renal cell carcinoma (RCC). The data are being presented in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary (GU) Cancers Symposium being held virtually.
Jan 20, 2021 07:00 am ET
AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Facility with Hercules Capital
AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates, to be added to the current tranched, $35 million debt facility secured with Hercules in August 2020 through an amendment to the amended and restated loan and security agreement (the “Loan Agreement”). Terms of the facility would remain otherwise unchanged from the Loan Agreement, with the loan bearing a maturity of 36 months, extendable up to 48 months, and an interest-only period of 12 months, extenda
Jan 15, 2021 08:00 am ET
AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma
AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO’s vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) drug candidate, in combination with IMFINZI® (durvalumab), AstraZeneca’s (LSE/STO/Nasdaq: AZN) human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with advanced or metastatic hepatocellular carcinoma (HCC). The results are being presented today in a poster session at the 2021 Ameri
Jan 07, 2021 07:00 am ET
AVEO Oncology Highlights Recent Progress and 2021 Outlook
AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook.
Jan 06, 2021 07:00 am ET
AVEO Oncology Announces Participation at Two Upcoming Investor Conferences
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences:
Jan 05, 2021 07:00 am ET
AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 5:20 p.m. Eastern Time. Following the presentation, Mr. Bailey will be joined by other members of AVEO’s management team for a question-and-answer session.
Nov 10, 2020 07:00 am ET
AVEO Oncology to Present at the Stifel 2020 Virtual Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time.
Nov 09, 2020 04:05 pm ET
AVEO Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update
AVEO Oncology (Nasdaq: AVEO) today reported financial results for the third quarter ended September 30, 2020 and provided a business update.
Nov 05, 2020 07:00 am ET
AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma
AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that previously reported results from the Phase 1b/2 TiNivo study of oral (PO) tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced or metastatic renal cell carcinoma (mRCC), were published in Annals of Oncology. The article, titled “TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Comb
Oct 19, 2020 07:00 am ET
AVEO Oncology Announces Appointment of David W. Crist as Vice President of Sales
AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO’s sales force in anticipation of the potential approval and launch of tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma.
Sep 15, 2020 04:05 pm ET
AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIVO-3 is the Company’s pivotal Phase 3 trial comparing tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, to sorafenib in third and fourth line renal cell carcinoma (RCC). The article, titled “Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal
Sep 08, 2020 07:00 am ET
AVEO Oncology Regains Full Global Rights to Ficlatuzumab
AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody which binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities. AVEO also announced today that it plans to fund the clinical manufacture of ficlatuzumab to enable a potential registrational Phase 3 clinical trial in head and neck squamous cell cancer (HNSCC), as well as additional potential development in Phase 2 studies in pancreatic cancer and acute myeloid leukemia (AML). Following
Sep 03, 2020 07:00 am ET
AVEO Oncology Announces Participation at Two Upcoming Investor Conferences
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences:
Aug 10, 2020 04:05 pm ET
AVEO Oncology Announces Restructuring of Existing Term Loan with Closing of New Tranched, $35 Million Debt Facility
AVEO Oncology (Nasdaq: AVEO) today announced the closing of a tranched, $35 million debt facility with Hercules Capital, Inc. (NYSE: HTGC) and its affiliates. The new facility has a maturity of 36 months, extendable up to 48 months, and an interest-only period of 12 months, extendable up to 30 months upon the achievement of performance milestones related to the approval and commercialization of tivozanib.
Aug 10, 2020 04:05 pm ET
AVEO Oncology Reports Second Quarter 2020 Financial Results and Provides Business Update
AVEO Oncology (Nasdaq: AVEO) today reported financial results for the second quarter ended June 30, 2020 and provided a business update.
Aug 05, 2020 04:05 pm ET
AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin
AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin). The milestone relates to acceptance by the Japanese Pharmaceuticals and Medical Devices Agency of an investigational new drug (IND) application for tivozanib in a non-oncology indication being developed by Kyowa Kirin.
Jun 19, 2020 04:05 pm ET
AVEO Announces Closing of Public Offering of Common Stock and Partial Exercise of Option to Purchase Additional Shares
AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters of their option to purchase an additional 1,225,000 shares, at a price to the public of $5.25 per share. The aggregate gross proceeds to AVEO from the offering were approximately $51.1 million, before deducting underwriting discounts and commissions and offering expenses payable by AVEO.
Jun 16, 2020 10:38 pm ET
AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock
AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to AVEO from the offering are expected to be approximately $44.6 million before deducting underwriting discounts and commissions and offering expenses. All of the shares in the offering are being sold by AVEO. AVEO has also granted the underwriters a 30-day option to purchase up to an additional 1,275,000 shares of common stock on the same terms and conditions. Closing of the
Jun 15, 2020 04:05 pm ET
AVEO Announces Proposed Public Offering of Common Stock
AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of $40.0 million of shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional $6.0 million of shares of its common stock. All of the shares in the offering are to be sold by AVEO. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Jun 01, 2020 01:15 pm ET
AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma
AVEO Oncology (NASDAQ: AVEO) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC). The FDA has assigned the application standard review and a Prescription Drug User Fee Act target action date of March 31, 2021. The FDA also indicated that they do not currently plan on convening an Oncologic Drug Advisory Committee (ODAC)
May 29, 2020 07:05 am ET
AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2
AVEO Oncology (NASDAQ: AVEO) today announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s (LSE/STO/NYSE: AZN) human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with hepatocellular carcinoma (HCC) who have not received prior systemic therapy, has demonstrated that the combination can be administered safely and the study has
May 29, 2020 07:00 am ET
AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured at ASCO 2020 Virtual Scientific Program and Submitted to U.S. FDA as Part of NDA Filing
AVEO Oncology (NASDAQ: AVEO) today announced the presentation of results from the final analysis of overall survival (OS) in its pivotal Phase 3 TIVO-3 trial comparing tivozanib, the Company’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI), to sorafenib in 3rd and 4th line renal cell carcinoma (RCC). The results, which have been submitted to the U.S. Food and Drug Administration (FDA) as part of the Company’s New Drug Application (NDA) submitted in March, are being featured today at the ASCO 2020 Virtual Scientific Program in a poster titled,
May 27, 2020 04:05 pm ET
AVEO Announces Change to Virtual Annual Meeting of Stockholders
AVEO Oncology (NASDAQ: AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees and communities, the location of its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) has been changed to a virtual meeting. As previously announced, the Annual Meeting will be held on June 10, 2020 at 10:00 a.m. Eastern Time, but will be held via live audio webcast. Stockholders will be able to attend th
May 01, 2020 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Southwest Airlines, AVEO Pharmaceuticals, Apache Corp, or Thermogenesis?
NEW YORK, May 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, LUV, AVEO, APA, and THMO.
Apr 30, 2020 07:00 am ET
AVEO Oncology Reports First Quarter 2020 Financial Results and Provides Business Update
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2020 and provided a business update.
Apr 29, 2020 02:30 pm ET
AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma at the ASCO 2020 Virtual Scientific Program
AVEO Oncology (NASDAQ: AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial comparing tivozanib, AVEO’s vascular endothelial growth factor receptor tyrosine kinase inhibitor, to sorafenib in 3rd and 4th line renal cell carcinoma, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program being held May 29-May 31, 2020.
Mar 31, 2020 04:05 pm ET
AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma
AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC).
Mar 27, 2020 04:40 pm ET
AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML). This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pandemic, which has impacted the feasibility of completing the study within the shelf-life of
Mar 16, 2020 04:05 pm ET
AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update.
Feb 19, 2020 09:08 am ET
AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split
AVEO Oncology (NASDAQ: AVEO) today announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective as of 5:00 p.m. Eastern Time today, February 19, 2020. AVEO’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis when the market opens on Thursday, February 20, 2020. The new CUSIP number for AVEO’s common stock following the reverse stock split is 053588 307.
Feb 12, 2020 04:26 pm ET
AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Journal of Cancer
AVEO Oncology (NASDAQ: AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in patients with advanced, inoperable hepatocellular carcinoma (HCC) in the British Journal of Cancer. The article, titled “A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma,” is available online first via
Jan 27, 2020 07:00 am ET
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). The results were presented during a poster session at the 2020 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium. A copy of the presentation, titled “Phase 1b Study of Gemcitabine, Nab-
Jan 06, 2020 07:00 am ET
AVEO Announces Appointment of Erick J. Lucera as Chief Financial Officer
AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Erick Lucera as chief financial officer. Mr. Lucera will be responsible for managing all aspects of the Company’s financial and accounting functions.
Dec 04, 2019 07:00 am ET
AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
AVEO Oncology (NASDAQ: AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®), the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma (RCC). The article, titled “Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, r
Nov 26, 2019 07:00 am ET
AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at 4:30 p.m. Eastern Time.
Nov 19, 2019 07:00 am ET
AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors
AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and life sciences industries.
Nov 18, 2019 06:00 am ET
AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
AVEO Oncology (NASDAQ: AVEO) today announced the presentation of updated data from the Phase 3 TIVO-3 trial. The data were presented on Saturday, November 16, 2019, at the 18th International Kidney Cancer Symposium in Miami, in an oral presentation titled “TIVO-3: A Phase 3 Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC) Overall Survival 2-Year Update” by Sumanta (Monty) Kumar Pal, M.D., Associate Clinical Professor, Department of Medical Oncology and Therapeutics Research, and Co-director, Kidney Cancer Program, at City of Hop
Nov 12, 2019 07:00 am ET
AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update.
Nov 07, 2019 07:00 am ET
AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML).
Nov 04, 2019 07:00 am ET
AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma
AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the Company’s proposal to proceed with a New Drug Application (NDA) for tivozanib.
Sep 30, 2019 07:00 am ET
AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma
AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Sep 26, 2019 07:00 am ET
AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 10:05 a.m. Eastern Time.
Sep 23, 2019 07:00 am ET
AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
The Phase 1b/2 study enrolled a total of 28 patients. The Phase 2 portion of the study (n=22) was designed to assess the safety, tolerability, and anti-tumor activity of the full dose and schedule of PO tivozanib (1.5 mg/QD for 21 days followed by a 7-day rest period), as established in the Phase 1b portion of the study (n=6), in combination with IV nivolumab (240 mg every 2 weeks). The combination was generally well tolerated and showed additive or synergistic activity for objective response rate and progression free survival (PFS) in both treatment naïve and previously treated patients with
Sep 10, 2019 09:31 am ET
Thinking about buying stock in AVEO Pharmaceuticals, CAN-FITE Biopharma, Francesca's, AT&T, or Tilray?
NEW YORK, Sept. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, CANF, FRAN, T, and TLRY.
Sep 10, 2019 06:30 am ET
AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®) to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma (RCC). These results include an OS hazard ratio (HR) below 1.00, favoring tivozanib (HR=0.99; 95% CI: 0.76-1.29; p=0.95). An OS hazard ratio assesses the relative risk of death for the entirety of the data set. TIVO-3 is the first and only positive
Aug 08, 2019 07:00 am ET
AVEO Reports Second Quarter 2019 Financial Results and Provides Business Update
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the second quarter ended June 30, 2019 and provided a business update.
Aug 01, 2019 06:00 am ET
Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology
Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) and AVEO Oncology (NASDAQ: AVEO) announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which includes the U.S. and EU. The agreement is an amendment to the terms of the 2006 tivozanib license agreement between Kyowa Kirin and AVEO which granted AVEO exclusive rights of tivozanib in all indications.
May 29, 2019 07:00 am ET
AVEO Oncology to Present at the 2019 BIO International Convention
AVEO Oncology (NASDAQ: AVEO) today announced that Mike Ferraresso, Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.m. EDT.
May 15, 2019 05:00 pm ET
AVEO Oncology Announces Presentations at the 2019 ASCO Annual Meeting
AVEO Oncology (NASDAQ: AVEO) today announced two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois.
May 09, 2019 07:00 am ET
AVEO Reports First Quarter 2019 Financial Results and Provides Business Update
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
May 01, 2019 07:00 am ET
AVEO Oncology to Participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit
AVEO Oncology (NASDAQ:AVEO) today announced that members of the management team will participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit on Wednesday, May 8, 2019. The conference is being held May 7-8 in New York.
Apr 26, 2019 08:30 am ET
FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVEO Pharmaceuticals, Inc. (“AVEO” or “the Company”) (NASDAQ:
Apr 25, 2019 09:09 pm ET
APRIL 26 DEADLINE: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AVEO Pharmaceuticals, Inc. (AVEO) and Encourages AVEO Investors Who Suffered Losses Exceedin
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired AVEO Pharmaceuticals, Inc....
Apr 25, 2019 10:57 am ET
CLASS ACTION UPDATE for CORT, AVEO, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Apr 25, 2019 09:00 am ET
FRIDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AVEO Pharmaceuticals, Inc. (“AVEO” or “the Company”) (NASDAQ: AVEO) for violations of §§10(b) and 20(a) of the Securities...
Apr 23, 2019 06:28 pm ET
AVEO FRIDAY DEADLINE ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors of Important April 26th Deadline in Securities Class Action Lawsuit – AVEO
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the “Class Period”) of the important April 26, 2019 lead...
Apr 23, 2019 04:05 pm ET
AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To Commercialization of FOTIVDA® in Spain
AVEO Oncology (NASDAQ:AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the reimbursement approval and commercial launch in Spain of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). Commercial launch in Spain is the third of five EU5 country launches to trigger a $2 million payment under the terms of AVEO’s license agreement with EUSA Pharma. In the European Union, Norway and Iceland, tivozanib is
Apr 23, 2019 03:00 pm ET
Class Action Alert CAG, DPLO & AVEO Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 19, 2019 10:39 am ET
SHAREHOLDER ALERT: CORT AVEO MBT ARA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 18, 2019 02:02 pm ET
APR 26 DEADLINE NOTICE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. – AVEO
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the “Class Period”). The...
Apr 18, 2019 10:11 am ET
CLASS ACTION UPDATE for CORT, AVEO, DPLO and MBT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Apr 16, 2019 05:34 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – AVEO
Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. (“Aveo” or the “Company”) (NASDAQ: AVEO) and certain of its officers and directors.   The class action, filed in United States District Court,...
Apr 16, 2019 10:46 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AVEO, DPLO, UMC and NIO
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 16, 2019 09:10 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within American Airlines Group, Petroleo Brasileiro S.A.- Petrobras, Gilead Sciences, Baozun, S&P Global, and AVEO Pharmaceuticals — New Re
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of American Airlines Group Inc. (NASDAQ:AAL), Petroleo Brasileiro S.A.- Petrobras...
Apr 15, 2019 05:46 pm ET
AVEO CLASS ACTION ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors of Important April 26th Deadline in Securities Class Action Lawsuit; Encourages Investors With Losses in Excess of
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the “Class Period”) of the important April 26, 2019 lead...
Apr 15, 2019 09:10 am ET
Research Report Identifies Lincoln National, Zayo Group, AVEO Pharmaceuticals, NV5 Global, WillScot, and Capstone Turbine with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Lincoln National Corporation (NYSE:LNC), Zayo Group Holdings, Inc. (NYSE:ZAYO),...
Apr 12, 2019 03:00 pm ET
Class Action Alert CAG, DPLO & AVEO Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 11, 2019 01:45 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AVEO, STMP, CAG and SYNH
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Apr 11, 2019 06:00 am ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AVEO Pharmaceuticals, Inc. (AVEO) and Encourages AVEO Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired AVEO Pharmaceuticals, Inc....
Apr 10, 2019 10:58 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AVEO, BRS, BPI and CRBP
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 09, 2019 08:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -AVEO
NEW YORK, April 9, 2019 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. ("Aveo" or the "Company") (NASDAQ: AVEO) and certain of its officers and directors. The class action, filed in United States District Court, Southern District of New York, and indexed under 19-cv-01722, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired AVEO securities between August 4, 2016 through January 31, 2019, both dates inclusive (the "Class Period"), seeking
Apr 09, 2019 08:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -AVEO
NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. ("Aveo" or the "Company") (NASDAQ: AVEO) and certain of its officers and directors. The class action, filed in United States District Court, Southern District of New York, and indexed under 19-cv-01722, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired AVEO securities between August 4, 2016 through January 31, 2019, both dates inclusive (the "Class Period"), s
Apr 08, 2019 04:59 pm ET
CLASS ACTION UPDATE for AVEO, AVP, DPLO and MBT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Apr 07, 2019 09:00 am ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – AVEO
Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. (“Aveo” or the “Company”) (NASDAQ: AVEO) and certain of its officers and directors.  The class action, filed in United States District Court,...
Apr 05, 2019 03:00 pm ET
Class Action Alert CAG, DPLO & AVEO Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 04, 2019 04:33 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AVEO, BRS, T and CRCM
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 03, 2019 04:01 pm ET
AVEO Pharmaceuticals, Inc. Announces Proposed Public Offering
AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced it has commenced an underwritten public offering of its shares of common stock, together with warrants to purchase shares of common stock. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock and/or warrants to be sold in the offering at the public offeri
Apr 03, 2019 11:19 am ET
CLASS ACTION UPDATE for AVEO, TAP, AVP and INGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Apr 03, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis Inc., Advanced Micro Devices, Aveo Pharmaceuticals, Dave & Buster's, or Riot Blockchain Inc.?
NEW YORK, April 3, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AMD, AVEO, PLAY, and RIOT.
Apr 03, 2019 06:00 am ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AVEO Pharmaceuticals, Inc. (AVEO) and Encourages AVEO Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired AVEO Pharmaceuticals, Inc....
Apr 02, 2019 06:16 pm ET
AVEO APRIL 26th DEADLINE: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action Lawsuit; Encourages Investors With Losses in Excess of $200K to C
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the “Class Period”) of the important April 26, 2019 lead...
Apr 02, 2019 07:00 am ET
AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 2:10 p.m. BST.
Apr 01, 2019 04:05 pm ET
AVEO and Biodesix Announce Positive Results from Phase Ib Ficlatuzumab-Cytarabine Trial in Patients with Relapsed and Refractory AML
AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia (AML). The results were presented in a poster session at the American Association for Cancer Research (AACR) 2019 Annual Meeting. The presentation, titled, “CyFi: Results from a phase Ib expansion cohort of ficlatuzumab (Fi)
Apr 01, 2019 10:44 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of UXIN, AVEO, AMR and UMC
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Mar 29, 2019 03:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LXRX, UXIN, AVEO and AMRN
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 28, 2019 03:00 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – AVEO
Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. (“Aveo” or the “Company”) (NASDAQ: AVEO) and certain of its officers and directors.  The class action, filed in United States District Court,...
Mar 28, 2019 03:00 pm ET
Class Action Alert CAG, DPLO & AVEO Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 28, 2019 09:31 am ET
Thinking about buying stock in Aveo Pharmaceuticals, Lululemon Athletica Inc., Navios Maritime, Quantenna Communications Inc., or Reebonz Ltd.?
NEW YORK, March 28, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, LULU, NMCI, QTNA, and RBZ.
Mar 28, 2019 07:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vanda Pharmaceuticals, AVEO Pharmaceuticals, Stamps.com, and Syneos and Encourages Investors to Contact
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Vanda Pharmaceuticals Inc., AVEO Pharmaceuticals, Inc., Stamps.com Inc., and Syneos Health, Inc.  Stockholders have until the...
Mar 27, 2019 11:15 am ET
CLASS ACTION UPDATE for UXIN, AVEO, AMRN and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 26, 2019 08:28 pm ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AVEO Pharmaceuticals, Inc. (AVEO) and Encourages AVEO Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired AVEO Pharmaceuticals, Inc....
Mar 26, 2019 12:46 pm ET
SHAREHOLDER ALERT: AVEO BRS CAG BPI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 26, 2019 10:59 am ET
AVEO: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against AVEO Pharmaceuticals Inc.– AVEO
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive. The lawsuit seeks to recover damages...
Mar 21, 2019 06:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – AVEO
Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. (“Aveo” or the “Company”) (NASDAQ: AVEO) and certain of its officers and directors.   The class action, filed in United States District Court,...
Mar 21, 2019 10:26 am ET
CLASS ACTION UPDATE for AVEO, STMP, AMR and MBT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 20, 2019 08:54 pm ET
DEADLINE NOTICE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. – AVEO
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the “Class Period”). The...
Mar 20, 2019 03:00 pm ET
HIIQ, AVEO & CVS Bronstein, Gewirtz & Grossman, LLC Class Action Reminder
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 20, 2019 09:42 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SPB, ASTE, VALE and AVEO
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Mar 19, 2019 10:37 am ET
SHAREHOLDER ALERT: ASTE AVEO STMP CAG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 16, 2019 05:23 pm ET
AVEO INVESTOR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. – AVEO
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the...
Mar 15, 2019 02:59 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AVEO Pharmaceuticals, Inc. (“AVEO” or “the Company”) (NASDAQ: AVEO) for violations of §§10(b) and 20(a) of the Securities...
Mar 15, 2019 11:29 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZIV, UXIN, AVEO and GE
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 14, 2019 09:32 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – AVEO
Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. (“Aveo” or the “Company”) (NASDAQ: AVEO) and certain of its officers and directors.   The class action, filed in United States District Court,...
Mar 14, 2019 04:05 pm ET
AVEO Reports Full Year 2018 Financial Results and Provides Business Update
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2018 and provided a business update.
Mar 14, 2019 03:00 pm ET
Class Action Update KHC, AVEO & CVS Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 13, 2019 03:28 pm ET
CLASS ACTION UPDATE for TYME, AVEO, CVS and CTL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 13, 2019 10:03 am ET
SHAREHOLDER ALERT: ARLO UXIN AVEO MHLD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 12, 2019 04:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MAXR, AVEO, AMRN and CVS
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 12, 2019 03:37 pm ET
AVEO DEADLINE ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against AVEO Pharmaceuticals Inc.– AVEO
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive. The lawsuit seeks to recover damages...
Mar 11, 2019 06:47 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of AVEO Pharmaceuticals, Inc. Investors
Law Offices of Howard G. Smith announces an investigation on behalf of AVEO Pharmaceuticals, Inc. investors (“AVEO” or the “Company”) (NASDAQ: AVEO) concerning the Company and its officers’ possible violations of federal securities laws. On...
Mar 08, 2019 04:52 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of AVEO Pharmaceuticals, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of AVEO Pharmaceuticals, Inc. (“AVEO” or the “Company”) (NASDAQ: AVEO) investors concerning the Company and its officers’ possible violations of federal securities laws. If...
Mar 08, 2019 12:00 pm ET
(AVEO) AVEO Pharmaceuticals, Inc. Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Final Deadline: April 26, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AVEO Pharmaceuticals, Inc. (“AVEO” or the “Company”) (NASDAQ: AVEO) and certain of its officers, on behalf of...
Mar 07, 2019 07:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – AVEO
Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. (“Aveo” or the “Company”) (NASDAQ: AVEO) and certain of its officers and directors.   The class action, filed in United States District Court,...
Mar 07, 2019 07:06 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of AVEO Pharmaceuticals, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of AVEO Pharmaceuticals, Inc. (“AVEO” or the “Company”) (NASDAQ: AVEO) investors concerning the Company and its officers’ possible violations of federal securities laws.
Mar 07, 2019 05:48 pm ET
AVEO INVESTOR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. - AVEO
NEW YORK, March 7, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for AVEO investors under the federal securities laws.
Mar 07, 2019 04:10 pm ET
AVEO PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the
Wolf Haldenstein Adler Freeman & Herz LLP announces that  a  federal securities class action  lawsuit has been  filed in  the United States  District Court for  the Southern  District of  New York  on behalf  of all  investors who  purchased  or...
Mar 06, 2019 10:27 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DNKEY, UXIN, AVEO and TAP
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 05, 2019 05:15 pm ET
RM LAW Announces Class Action Lawsuit Against AVEO Pharmaceuticals, Inc.
BERWYN, Pa., March 5, 2019 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ: AVEO) between August 4, 2016 and January 31, 2019, inclusive (the "Class Period").
Mar 04, 2019 06:05 pm ET
Robbins Arroyo LLP: AVEO Pharmaceuticals, Inc. (AVEO) Sued for Misleading Shareholders
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of AVEO Pharmaceuticals, Inc. (NasdaqCM: AVEO) filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1934 between August 4, 2016 and January 31, 2019. AVEO develops targete
Mar 04, 2019 04:54 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of AVEO Pharmaceuticals, Inc. Investors
Law Offices of Howard G. Smith announces an investigation on behalf of AVEO Pharmaceuticals, Inc. investors (“AVEO” or the “Company”) (NASDAQ: AVEO) concerning the Company and its officers’ possible violations of federal securities laws.
Mar 04, 2019 11:36 am ET
SHAREHOLDER ALERT: AVEO KHC STMP SYNH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 03, 2019 06:20 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Diplomat Pharmacy, Vanda Pharmaceuticals, and AVEO Pharmaceuticals and Encourages Investors to Contact
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Diplomat Pharmacy, Inc., Vanda Pharmaceuticals Inc., and AVEO Pharmaceuticals, Inc.  Stockholders have until the deadlines...
Mar 03, 2019 08:35 am ET
AVEO INVESTOR ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action Lawsuit – AVEO
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the “Class Period”) of the important April 26, 2019 lead plaintiff deadline in the securities class action lawsuit filed against the company. The lawsuit seeks to recover damages for AVEO investors under the federal securities laws.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.